During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|July 1, 2010
Formulary Digital Edition, July 2010
Hemophilia: Etiology, complications, and current options in management; Rifaximin: A nonabsorbable, broad-spectrum antibiotic for reduction in the risk for recurrence of overt hepatic encephalopathy; Agents in late-stage development for the treatment of female and male cancers
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
4
Experts say cost barriers and stigma keep eligible adults from lung cancer screening
5